

34 — SSMO, SSH — Joint Session

## Oral presentations Experimental hematology / oncology

Wednesday, 19 Nov 2025, 1:45 p.m. - 3:15 p.m., Shanghai 1-2

Chair: Steffen Böttcher (University Hospital Zurich), Benjamin Kasenda (Universitätsspital Basel)

#### Clinical transcriptomics reveal therapeutically highly relevant alterations in adult Ph- B-ALL

Presentation time: 9 min Discussion time: 3 min

Speaker: Rieger (UniversitätsSpital Zürich)

### Dual inhibition of JAK2 and Gas6/TAM signaling mitigates disease progression and vascular complications in polycythemia vera

Presentation time: 9 min Discussion time: 3 min

Speaker: Knopp (Inselspital)

## JAK2 signalling to HNRNPA1 represses retrotransposon activity in haematopoietic stem cells and protects the genome.

Presentation time: 9 min Discussion time: 3 min

Speaker: Deuel (UniversitätsSpital Zürich)

# Divergent Effects of Tet2- and Dnmt3a-mutant Clonal Hematopoiesis on Breast Cancer **Progression Upon Aging**

Presentation time: 9 min Discussion time: 3 min

Speaker: Gönüllü (University Hospital Zurich)

#### Drivers of Therapy-Related Clonal Hematopoiesis and Its Progression to Myeloid Neoplasms

Presentation time: 9 min Discussion time: 3 min

Speaker: Koch (University of Zurich and University Hospital Zurich)

#### A Human CRISPR-Engineered MLLr Leukemia Model Enables Functional Analysis Across MLL **Fusion Variants**

Presentation time: 9 min Discussion time: 3 min

Speaker: Radszuweit (University Hospital Zurich)



# Enhancing bispecific T-cell engagers and activators by CD33 selective co-stimulation

Presentation time: 9 min Discussion time: 3 min

Speaker: Hofstetter (University Hospital Zurich)